Physician profile
Wesley Budd
NPI 1154880110
$887.11
in general payments reported to CMS, 2019-2025
20 companies · $89.26 in 2025
The $89.26 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $11.79 · 2021: $101 · 2022: $448 · 2023: $116 · 2024: $121 · 2025: $89.26.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $326.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $326.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $149.88 | 2022-2023 | Mavenclad |
| Genzyme Corporation | $119.07 | 2022-2023 | |
| Neurelis, INC. | $74.83 | 2023-2025 | Valtoco |
| Sk Life Science, INC. | $71.43 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $67.98 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $67.52 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $46.97 | 2021 | |
| Horizon Therapeutics Plc | $44.07 | 2022 | |
| Ucb, INC. | $38.56 | 2025 | Fintepla |
| Takeda Pharmaceuticals U.S.A., INC. | $25.31 | 2022 | |
| Jazz Pharmaceuticals INC. | $24.91 | 2024 | |
| Averitas Pharma INC. | $24.53 | 2023 | Qutenza |
| Lundbeck LLC | $23.82 | 2021 | |
| Alexion Pharmaceuticals, INC. | $18.14 | 2022 | |
| Livanova USA, INC. | $17.43 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $17.37 | 2022 | |
| Celgene Corporation | $16.60 | 2021 | |
| Genentech USA, INC. | $13.69 | 2022 | |
| Almatica Pharma LLC | $13.21 | 2021 | |
| Avanir Pharmaceuticals, INC. | $11.79 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wesley Budd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.